Epidermal growth factor receptor (EGFR) can undergo post-translational modifications, including phosphorylation, glycosylation and ubiquitylation, leading to diverse physiological consequences and modulation of its biological activity. There is increasing evidence that methylation may parallel other post-translational modifications in the regulation of various biological processes. It is still not known, however, whether EGFR is regulated by this post-translational event. Here, we show that EGFR Arg 1175 is methylated by an arginine methyltransferase, PRMT5. Arg 1175 methylation positively modulates EGF-induced EGFR trans-autophosphorylation at Tyr 1173, which governs ERK activation. Abolishment of Arg 1175 methylation enhances EGF-stimulated ERK activation by reducing SHP1 recruitment to EGFR, resulting in augmented cell proliferation, migration and invasion of EGFR-expressing cells. Therefore, we propose a model in which the regulatory crosstalk between PRMT5-mediated Arg 1175 methylation and EGF-induced Tyr 1173 phosphorylation attenuates EGFR-mediated ERK activation.
binding activity of the mature surface receptor. Serine/threonine phosphorylation by protein kinase C (PKC), mitogen-activated protein kinase (MAPK) and calcium/calmodulin-dependent protein kinase II (CaMKII) modulates receptor tyrosine kinase activity and internalization. Cbl-mediated multiple polyubiquitylation regulates EGFR degradation and controls the duration of EGFR activation.
Recent evidence indicates that protein methylation, similarly to other types of post-translational modification, has significant biological functions 5 . Methylation at lysine and arginine residues has been linked to transcription regulation, RNA metabolism, DNA damage repair and signal transduction. As protein methylation comes of age, it is of interest to investigate whether EGFR is regulated by this post-translational modification.
To determine whether EGFR is methylated, we carried out in vivo methylation assays. A431 cells were metabolically labelled with l-[methyl-
3 H]methionine in the presence of protein synthesis inhibitors (Fig. 1a , lanes 1-6), and methylation was detected by fluorography. One radioactive signal corresponding to the molecular weight of EGFR could be detected in the immunoprecipitates of anti-EGFR antibody (lane 2), but not in those of the control antibody (lane 1). Simultaneously, metabolic labelling using l-[
35 S]methionine was carried out in parallel to monitor the activity of protein synthesis inhibitors (lanes [7] [8] [9] [10] . The absence of l-[
35 S]methionine incorporation in the presence of the inhibitors (compare lane 10 with lane 9) indicated that the radiolabelling in lane 2 was the result of post-translational modification and not translational incorporation. Collectively, these findings indicate that EGFR is methylated. To further confirm EGFR methylation and identify methylation site(s), mass spectrometry was 
Higher magnification used to analyse endogenous EGFR immunopurified from A431 cells and the result shows that EGFR Arg 1175 is monomethylated (Fig. 1b) .
To facilitate detection of EGFR Arg 1175 monomethylation, we raised a polyclonal antibody that specifically recognizes a monomethylated peptide corresponding to the EGFR amino acid 1171-1182 region where Arg 1175 is monomethylated, but not unmodified and dimethylated peptides ( Fig. 1c and Supplementary Fig. S1a ). Moreover, this antibody recognized only ectopic full-length EGFR wild type (WT) and not the methylation-site mutant (R1175K) in cells (Fig. 1d) . In peptide competition assays, the antibody activity was neutralized only by the monomethylated EGFR peptide ( Fig. 1e and Supplementary  Fig. S1b ). Thus, this antibody specifically recognizes Arg-1175-methylated EGFR. In addition to ectopic EGFR proteins, the antibody works well in endogenous EGFR detection (Fig. 1f,g ).
Arginine methylation is mediated by enzymes of the protein arginine methyltransferase (PRMT) family 6 . To screen known PRMTs to determine whether they are responsible for EGFR Arg 1175 methylation, we used a co-immunoprecipitation assay to examine whether EGFR physically interacts with PRMT1, 2, 3, 4, 5, 6 or 8. The results indicate that EGFR binds to PRMT5 and PRMT8 (Fig. 2a) . Next, in vitro methylation assays showed PRMT5 and PRMT8 indeed methylated Arg 1175 of EGFR peptide (Fig. 2b) . In human tissues, PRMT5 is ubiquitously expressed, but PRMT8 expression is restricted to the brain 7 . Using confocal immunofluorescence staining, we found that in breast cancer cells EGFR is mainly associated with the cell membrane region, where some PRMT5 is also found (Fig. 2c) Fig. S1c ).
In vitro protein binding assays using recombinant PRMT5 and EGFR proteins indicate that PRMT5 does not directly bind to EGFR (data not shown). Similarly to the interactions between other PRMTs with their substrates [7] [8] [9] , PRMT5 associates with EGFR mainly through its catalytic core domain ( Supplementary Fig. S1d ). Moreover, we found that the PRMT5-EGFR association ( Supplementary Fig. S2a, top) and the Arg 1175 methylation status ( Supplementary Fig. S2a , bottom) remained consistent before and after EGF-mediated EGFR activation, indicating that EGF stimulation and EGFR kinase activity are not required for Arg 1175 methylation.
EGFR signalling is initiated by extracellular ligand binding, which induces activation of the intracellular kinase domain, resulting in trans-autophosphorylation of multiple tyrosine residues in the carboxyterminal tail region. Phosphotyrosines recruit cytosolic signalling molecules and trigger a series of intracellular pathways, culminating in cell proliferation, migration, invasion and tumourigenicity [1] [2] [3] . To investigate whether EGFR Arg 1175 methylation is involved in the EGFR functionality, we generated MCF7 stable transfectants containing EGFR (WT), EGFR (R1175K) or empty vector (designated as MCF7-EGFR (WT), MCF7-EGFR (R1175K) and MCF7-vector, respectively) for serial functional studies ( Fig. 3a and Supplementary Fig. S2b ). Using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assays, we observed that MCF7-EGFR (R1175K) cells grew more quickly than MCF7-EGFR (WT) cells (Fig. 3a) . Moreover, in an orthotopic breast cancer mouse model, MCF7-EGFR (R1175K) cells proliferated and induced mammary tumour formation more efficiently than MCF7-EGFR (WT) cells (Fig. 3b) . In addition, MCF7-EGFR (R1175K) cells also exhibited greater migration (Fig. 3c) and invasion (Fig. 3d ) abilities than MCF7-EGFR (WT) cells. These results collectively indicate that Arg 1175 methylation suppresses EGFR functionality.
To further investigate how Arg 1175 methylation affects EGFR functionality, we compared tyrosine phosphorylation of EGFstimulated EGFR (WT) and EGFR (R1175K) with site-specific antibodies against phospho-Tyr 845, Tyr 992, Tyr 1045, Tyr 1068, Tyr 1086, Tyr 1148 and Tyr 1173. Interestingly, EGF stimulation efficiently induced EGFR (R1175K) phosphorylation at all tyrosine residues tested except Tyr 1173 ( Fig. 4a and Supplementary Fig. S2c ). To rule out the possibility that the decrease of Tyr 1173 phosphorylation was due to protein conformational misfolding caused by R1175K mutagenesis, we also inhibited EGFR Arg 1175 methylation using multiple PRMT5 siRNAs as a comparison. Consistently, PRMT5 knockdown specifically downregulated EGF-induced Tyr 1173 phosphorylation and not other tyrosine phosphorylations ( phosphorylated the monomethylated peptide more efficiently than the unmodified peptide (Fig. 4c ). Phospho-Tyr 1173 serves as one of the docking sites for the cytosolic signalling molecules Src homology 2 (SH2)-domain-containing transforming protein (SHC) and growth factor receptor-bound protein 2 (Grb2). Recruitment of SHC and Grb2 to EGFR elicits extracellular signal-regulated kinase (ERK) activation [10] [11] [12] . PhosphoTyr 1173 is also the main binding site for SH2-domain-containing protein tyrosine phosphatase 1 (SHP1). In contrast, binding of SHP1 to EGFR results in attenuation of EGFR-dependent ERK activation 13 . As Arg 1175 methylation positively regulates Tyr 1173 phosphorylation, we further investigated whether it regulates the association between EGFR and these cytosolic molecules. Using a co-immunoprecipitation assay, we found that downregulation of Arg 1175 methylation by R1175K mutagenesis or by PRMT5 siRNA treatment had no significant effect on EGFR-Grb2 and EGFR-SHC associations, but inhibited EGFR-SHP1 binding (Fig. 5a,b) , indicating that Arg 1175 methylation enhances EGFR-SHP1 binding on EGFR activation and may inhibit EGFR-mediated ERK activation. We also investigated the effect of EGFR Arg 1175 methylation on the activation status of key molecules within four major EGFR downstream signalling pathways, including ERK1 (phospho-ERK1 Arg 1175 methylation affected only EGFR-mediated activation of ERK (Fig. 5c,d) , and not AKT, PLC-γ or STAT3. On EGF treatment, ERK was transiently activated and then rapidly deactivated. Notably, ERK activation status remained higher and lasted longer when EGFR Arg 1175 methylation was suppressed by R1175K mutagenesis or by PRMT5 siRNA transfection (Fig. 5c,d , compare even lanes and odd lanes). These results reveal that EGFR Arg 1175 methylation specifically downregulates EGFR-mediated ERK activation. In support of this, ERK inhibitor treatment suppressed the enhanced cell growth, migration and invasion abilities of MCF7-EGFR (R1175K) cells ( Supplementary Fig. S3a-c) .
In summary, we found that EGFR Arg 1175 methylation positively modulates Tyr 1173 phosphorylation, which enhanced EGFR-SHP1 binding and resulted in suppression of EGFR-mediated ERK activation. This regulatory mechanism indicates that the activation of EGFR downstream pathways could be differentially regulated by EGFR methylation status. Recent identification of histone arginine demethylase indicates that arginine methylation of non-histone proteins may be reversible 14 . Any signalling event leading to a change in Arg 1175 methylation status would specifically modulate the EGF-EGFR-ERK signalling axis. This mechanism also implies the existence of an EGFR protein modification code, which is reminiscent of the histone code encoded by substantially cross-regulated histone modifications 15, 16 . In addition to Arg 1175 methylation, we identified seven potential lysine and arginine methylation sites in the kinase domain and C-terminal tail of EGFR ( Supplementary Fig. S4a ) with some that are close to, or even overlap with, other known modifications ( Supplementary Fig. S4b ). We predict that further elucidation of the function of individual methylations or the interrelationships between methylations and other modifications would expand our knowledge of the EGFR signalling network.
Moreover, our results provide further evidence showing that the phosphorylation of EGFR on Tyr 1173 has a suppressive effect on ERK signalling. Previous literature gave phospho-Tyr 1173 two opposite roles in EGFR signalling and indicated that Tyr 1173 phosphorylation may cooperate with phospho-Tyr 992, Tyr 1068, Tyr 1086 and Tyr 1148 to elicit ERK signalling through recruitment of SHC and Grb2 (refs 10-12,17), or may work alone to attenuate ERK activation through SHP1 binding 13 . However, to the best of our knowledge, there is no systematic analysis of the interrelationship between these two groups of proteins and phospho-Tyr 1173. Here, we show that EGFR recruitment of these signalling molecules is a time-dependent process. On EGF stimulation, SHC and Grb2 are immediately recruited to EGFR whereas SHP1 binds to EGFR only at the later stage (∼30 min later after stimulation). Downregulation of Tyr 1173 phosphorylation diminishes the recruitment only of SHP1, but not SHC or Grb2. These data imply that a main role of Tyr 1173 phosphorylation is to recruit SHP1 at the later stage of EGFR activation to inactivate ERK rather than recruit SHC and Grb2 for ERK activation. The minor effect of phospho-Tyr 1173 downregulation on SHC and Grb2 recruitment could be due to the redundancy in both specificity and function of the different EGFR phosphorylation sites 2, 18 . To further address the role of phospho-Tyr 1173 on ERK activation, we made a MCF7-EGFR (Y1173F) stable transfectant and found that it grew faster and exhibited higher tumour formation abilities than the MCF7-EGFR (WT) cells ( Supplementary Fig. S3d-f) , indicating that phospho-Tyr 1173 has a major suppressive effect on ERK signalling.
The association of SHP1 with EGFR results in suppression of EGFR-mediated ERK activation. However, present knowledge has different interpretations of the action of SHP1 on the EGFR signalling, such that SHP1 binding to the EGFR can cause an overall decrease in tyrosine phosphorylation status of the receptor and attenuation of the receptor signalling both in transient co-expression systems and in stably SHP1-transfected cells 13, 19, 20 . However, other studies showed that repression of endogenous SHP1 expression by SHP1 siRNA does not affect full EGFR tyrosine phosphorylation 21 . This contradiction raises the question of how endogenous SHP1 is involved in the EGFR signalling regulation. To clarify this issue, we knocked down endogenous SHP1 expression by SHP1 siRNA and examined its effect on EGF-stimulated EGFR phosphorylation and downstream signalling activation (Supplementary Fig. S5a) . The results show that SHP1 knockdown extends ERK activation and, in line with previous studies, does not affect the EGFR tyrosine phosphorylation status, indicating that endogenous SHP1 may dephosphorylate other molecules rather than EGFR to attenuate ERK activation.
EGFR activates ERK through the EGFR-SHC-Grb2-SOS-RAS-RAF-MEK-ERK pathway (SOS, son of sevenless). On EGF stimulation, the SHC-Grb2-SOS complex is recruited to EGFR. It has been reported that these three molecules are subject to tyrosine phosphorylation [22] [23] [24] . Next, we tested whether they are potential targets of SHP1. We found that EGF stimulation induces tyrosine phosphorylation of SHC and SOS, and knockdown of endogenous SHP1 can extend the phosphorylation status of SOS ( Supplementary Fig. S5b ), indicating that SOS may be a potential target of endogenous SHP1 to reduce the activity of ERK. Given that phospho-Tyr 1173 is the main binding site of SHP1, we further tested whether Tyr 1173 is involved in the regulation of SOS tyrosine phosphorylation, and found SOS phosphorylation status lasted longer in the EGFR (Y1173F) cells than in the EGFR (WT) cells (Supplementary Fig. S5c ). Taken together, these data imply that phospho-Tyr 1173 recruits endogenous SHP1 to attenuate ERK activation by reducing the phosphorylation of SOS, rather than EGFR. Moreover, a similar pattern was also observed in the EGFR (R1175K) cells (Supplementary Fig. S5c ), further indicating that Arg 1175 methylation downregulates ERK activation by enhancing Tyr 1173 phosphorylation.
Here, we show that EGFR Arg 1175 methylation status is not regulated by EGF stimulation. During the preparation of this manuscript, other studies showed that PRMT5 methyltransferase activity is regulated by methylosome protein 50 (Mep50), whose binding to PRMT5 is required for the methyltransferase activity of PRMT5 (refs 25,26) . Mep50 exhibits distinctive subcellular distribution patterns in different pathological stages of breast cancer 27 . In malignant breast epithelia, Mep50 is expressed in the nucleus, whereas in their benign counterparts, Mep50 prefers cytoplasmic localization, which has been demonstrated to inhibit cell growth 27 . However, the mechanism is unclear. As our data support a model in which methylation of EGFR by PRMT5 suppresses cell growth, it is possible that cytoplasmic Mep50 inhibits cell growth through PRMT5-mediated EGFR methylation.
To this end, we tested whether cytoplasmic expression of Mep50 upregulates EGFR methylation, and found ectopic expression of nuclear exporting signal (NES)-fused Mep50, rather than nuclear localization signal (NLS)-fused Mep50, increased EGFR Arg 1175 methylation in the MCF7-EGFR (WT) cells (Supplementary Fig. S5d ), indicating that cytoplasmic Mep50 can upregulate EGFR Arg 1175 methylation. Next, we evaluated the role of EGFR methylation in cytoplasmic Mep50-mediated cell growth suppression. MCF7-EGFR (WT) cells but not MCF7-EGFR (R1175K) cells were sensitive to NES-Mep50-mediated cell growth suppression (Supplementary Fig. S5e ), indicating that cytoplasmic Mep50 may inhibit cell growth by upregulating EGFR Arg 1175 methylation. Collectively, these data indicate that EGFR Arg 1175 methylation could be regulated by the subcellular distribution of Mep50, and future work will be directed towards elucidation of the role of EGFR methylation in different pathological stages of breast cancer. R1175K and PRMT5 R368A mutageneses were generated using the QuickChange Site-Directed Mutagenesis Kit according to the manufacturer's protocol (Stratagene). Epidermal growth factor (EGF; Sigma) and U0126 (Cell Signaling) were prepared according to the manufacturers' instructions. The following peptides were chemically synthesized by QCB for antibody production in mice, dot blots, peptide competition assays and in vitro methylation assays. Unmodified peptide: NH 2 -CAEYLRVAPQSSE-COOH; methylated peptides: NH 2 -CAEYL(monomethyl-R)VAPQSSE-COOH, NH 2 -CAEYL(symmetric dimethyl-R)VAPQSSE-COOH and NH 2 -CAEYL(asymmetric dimethyl-R)VAPQSSE-COOH. Histone H4 peptide with monomethyl R3 was purchased from Abcam. Anti-EGFR antibody (Ab-12, 1:5,000; Thermo Scientific) and anti-EGFR antibody (06-847, 1:5,000; Millipore) were used to detect full-length EGFR and EGFR peptides, respectively. For detection of EGFR tyrosine phosphorylations, antibody against phosphotyrosine (4G10, 1:5,000; Millipore) was used to detect total tyrosine phosphorylations, and site-specific antibodies against phospho-Tyr 845, -Tyr 992, -Tyr 1045, -Tyr 1068, -Tyr 1086, -Tyr 1148 and -Tyr 1173 (Cell Signaling and Abcam) were used (1:2,000) to detect individual phosphotyrosines. Antibodies to ERK (1:5,000; Millipore), SHP1 (1:2,000; Millipore) and SHC (1:5,000; Millipore), antibodies to STAT3 (1:2,000; Santa Cruz) and SOS (1:2,000; Santa Cruz), and antibodies to AKT (1:2,000; Cell Signaling), PLC-γ (1:2,000; Cell Signaling), phospho-ERK (1:5,000; Cell Signaling), phospho-AKT (1:2,000; Cell Signaling), phospho-STAT3 (1:2,000; Cell Signaling), phospho-PLC-γ (1:2,000; Cell Signaling) and Grb2 (1:2,000; Cell Signaling) were used to detect the EGFR downstream pathways. Anti-PRMT5 (1:5,000) and anti-tubulin (1:5,000) antibodies were from Sigma. Anti-GFP (1:5,000) antibody was from Thermo Scientific. For immunofluorescence staining, antibodies were diluted 1:200. For immunoprecipitation, 5 µg of anti-EGFR (Ab-13; Thermo Scientific), anti-Grb2, anti-SHC or anti-SOS antibodies were used per 1 mg of total protein in 1 ml of cell lysates.
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In vivo methylation assay. For in vivo methylation of EGFR, a procedure modified from a previously described method 28 was used. A431 cells were incubated for 1 h in Dulbecco's modified Eagle's medium (DMEM; GIBCO) supplemented with 10% fetal bovine serum (FBS), 100 µg ml −1 cycloheximide (Sigma) and 40 µg ml −1 chloramphenicol (Sigma). Then, cells were washed twice with methionine-depleted DMEM (GIBCO) and incubated in the same medium containing 10 µCi ml −1 l-[methyl-
3 H]methionine (Amersham Biosciences), 10% dialysed FBS (GIBCO), 100 µg ml −1 cycloheximide and 40 µg ml −1 chloramphenicol. After labelling for 5 h, endogenous EGFR was immunopurified and analysed by SDS-PAGE.
3 H-methyl incorporation was visualized by fluorography. To monitor the effect of protein synthesis inhibitors, A431 cells were also labelled with 10 µCi ml −1 l-[
35 S]methionine (MP Biomedicals) using a procedure almost exactly the same as the one described above, with or without protein synthesis inhibitors. After labelling, whole-cell lysates were prepared, analysed by SDS-PAGE, and detected by autoradiography.
In vitro methylation assay. HA-PRMT3, HA-PRMT5 and HA-PRMT8 were expressed in HEK293 cells and immunopurified using HA-agarose (Sigma). The enzymes immobilized on the beads were then incubated with unmodified peptide (50 µg) in the presence of 2.
µCi S-adenosyl-l-[methyl-
3 H]methionine (85 Ci mmol −1 from a 0.55 mCi ml −1 stock solution; MP Biomedicals) for 1 h at 30 • C in a final volume of 50 µl of phosphate-buffered saline (PBS). One microgram of peptide was spotted onto polyvinylidene difluoride (PVDF) membranes and detected using anti-EGFR or anti-EGFR methylated-Arg-1175 antibodies. Five micrograms of peptide was spotted onto P81 papers, washed, and counted by liquid scintillation.
An in vitro methylation assay was also carried out as follows. GST-PRMT5 and GST-EGFR (ICD) were expressed in HEK293 cells and purified using glutathione resin (GE Healthcare). GST-PRMT5 and GST-EGFR (ICD) proteins were incubated in the presence of 2.
3 H]methionine (85 Ci mmol −1 from a 0.55 mCi ml −1 stock solution) for 1 h at 30 • C in a final volume of 50 µl PBS. Subsequently, samples were analysed by SDS-PAGE and EGFR methylation was detected using fluorography and anti-EGFR methylated-Arg-1175 antibody.
In vitro kinase assay. A procedure modified from a previously published method 29 was used. HA-EGFR was expressed in HEK293 cells and immunopurified using HA-agarose. The EGFR proteins immobilized on the beads were then incubated with unmodified or monomethylated peptides (50 µg) in a total volume of 50 µl of reaction buffer containing 5 mM HEPES (pH 7.4), 50 µM Na 3 VO 4 , 5 mM MgCl 2 , 2 mM MnCl 2 , 40 µg ml −1 bovine serum albumin, 250 mM ammonium sulphate, 25 µM ATP, and 62.5 µCi ml −1 [γ-32 P]ATP (MP Biomedicals). Reactions were carried out at 30 • C and stopped by using 8.5% phosphoric acid. One microgram of peptide was spotted onto PVDF membranes and detected using anti-EGFR or anti-EGFR phospho-Tyr 1173 antibodies. Five micrograms of peptide was spotted onto P81 papers, washed and counted by liquid scintillation.
siRNA transfection and siRNA-resistant mutant of PRMT5. Cells were transfected individually with three PRMT5 siRNA oligonucleotides (#1: 5 -UGGCACAACUUCCGGACUUUU-3 , #2: 5 -CAACAGAGAUCCUAUGAUU-3 or #3: 5 -CGAAAUAGCUGACACACUA-3 ) or two EGFR siRNA oligonucleotides (#1: 5 -CAAAGUGUGUAACGGAAUA-3' or #2: 5 -CCAUAAAUGCUACGAAUAU-3 ) or one SHP1 siRNA (5 -GGAACAAAUGCGUCCCAUA-3 ) with DharmaFECT 1 (Dharmacon), and used for experiments 96 h after transfection. A non-targeting siRNA (5 -UGGUUUACAUGUCGACUAA-3 ) was used as control. To rescue the phenotype of PRMT5 siRNA, an siRNA-resistant mutant of PRMT5 (RR-PRMT5) was created by substituting five nucleotides in the PRMT5 siRNA #1 targeting region (C570T, C573T, C576T, C577A and G579A).
Mass spectrometry. EGFR was isolated by immunoprecipitation with anti-EGFR
antibody and analysed by SDS-PAGE. The protein band corresponding to EGFR was excised and subjected to in-gel digestion with trypsin. After being isolated from the gel, samples were analysed by nanoelectrospray mass spectrometry, using an Ultimate capillary LC system (LC Packings) coupled to a QSTAR XL quadrupole time-of-flight mass spectrometer (Applied Biosystem/MDS Sciex).
Confocal microscopy analysis. Cultured cells were washed three times with PBS, fixed in 4% paraformaldehyde for 15 min, permeabilized with 0.5% Triton X-100 for 15 min, and incubated with 5% bovine serum albumin for 1 h. Cells were then incubated with the primary antibodies overnight at 4 • C. Cells were washed with PBS and then further incubated with the appropriate secondary antibody diluted at 1:500 and tagged with fluorescein isothiocyanate (FITC), Texas Red or Alexa 647 (Molecular Probes) for 45 min at room temperature. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI) before mounting. Confocal fluorescence images were captured using a Zeiss LSM710 laser microscope. In all cases, optical sections through the middle planes of the nuclei, as determined using nuclear counterstaining, were obtained.
Cell proliferation assay. Cells (5 × 10 3 cells per well) were seeded in 96-well plates, and relative cell amounts were determined by the MTT colorimetric method on a daily basis. MTT (Sigma) at 1 mg ml −1 was added to each well. After 2-h incubation, the medium was removed, and the MTT was dissolved in 100 µl of dimethylsulphoxide. The absorbance was measured at 570 nm, and the relative proliferation index for each day was determined using the absorbance at day 0 as the standard.
Migration and invasion assay. Cell migration and invasion were analysed using Biocoat Control inserts and Biocoat Matrigel invasion chambers (BD Biosciences), respectively. Cells (2 × 10 5 ) in DMEM medium with 0.1% FBS were added to the upper chamber and allowed to penetrate a porous (8 µm), uncoated membrane or a Matrigel-coated membrane to the bottom chamber containing DMEM medium with 10% FBS. Cells on the top surface of the membrane were removed 72 h after incubation, and the remaining cells on the bottom surface were fixed with 4% paraformaldehyde, stained with 0.5% crystal violet and counted from four random fields of each membrane using a bright-field microscope. The average cell number per field for each membrane was used to calculate the mean and s. Figure S1 (Hung, NCB-H18572) 
